List of progestogens available in the United States

This is a complete list of progestogens (progesterone and progestins) and formulations that are approved by the FDA and available in the United States. Progestogens are used as hormonal contraceptives, in hormone replacement therapy for menopausal symptoms, and in the treatment of gynecological disorders.

For contraception

Combined contraceptives

Combined oral contraceptive pills

  • Estradiol valerate and dienogest (Natazia)
  • Ethinylestradiol and desogestrel (Bekyree, Cyclessa, Desogen, Emoquette, Enskyce, Isibloom, Kariva, Kimidess, Mircette, Ortho-Cept, Pimtrea, Velivet, Viorele, Volnea)
  • Ethinylestradiol and drospirenone [and/or levomefolate calcium] (Beyaz, Loryna, Melamisa, Nikki, Safyral, Syeda, Yaela, Yasmin, Yaz)
  • Ethinylestradiol and etynodiol diacetate (Demulen 1/35-21, Demulen 1/35-28, Demulen 1/50-21, Demulen 1/50-28, Kelnor, Zovia 1/35E-21, Zovia 1/35E-28, Zovia 1/50E-21, Zovia 1/50E-28)
  • Ethinylestradiol and levonorgestrel (Alesse, Altavera, Ashlyna, Aviane-21, Aviane-28, Ayuna, Daysee, Elifemme, Enpresse-21, Enpresse-28, Falmina, Fayosim, Introvale, Kurvelo, Lessina-21, Lessina-28, Levlite, Levonest, Levonorgestrel and Ethinyl Estradiol, Levora 0.15/30-21, Levora 0.15/30-28, LoSeasonique, Lybrel, Marlissa, Myzilra, Nordette-21, Nordette-28, Orsythia, Portia-21, Portia-28, Preven Emergency Contraceptive Kit, Quartette, Quasense, Seasonale, Seasonique, Setlakin, Triphasil-21, Triphasil-28, Trivora-21, Trivora-28, Vienva)
  • Ethinylestradiol and norethisterone [and/or ferrous fumarate (Fe)] (Alyacen 1/35, Alyacen 7/7/7, Alyacen 777, Aranelle, Balziva-21, Balziva-28, Brevicon 21-Day, Brevicon 28-Day, Briellyn, Cyclafem 0.5/35, Cyclafem 1/35, Cyclafem 7/7/7, Dasetta 1/35, Dasetta 7/7/7, Femcon Fe, Gencept 10/11-21, Gencept 10/11-28, Gildagia, Kaitlib Fe, Modicon 21, Modicon 28, N.E.E. 1/35 21, N.E.E. 1/35 28, Norcept-E 1/35 21, Norcept-E 1/35 28, Norethin 1/35E-21, Norethin 1/35E-28, Norinyl 1+35 21-Day, Norinyl 1+35 28-Day, Norquest Fe, Nortrel 0.5/35-21, Nortrel 0.5/35-28, Nortrel 1/35-21, Nortrel 1/35-28, Nortrel 7/7/7, Ortho-Novum 1/35-21, Ortho-Novum 1/35-28, Ortho-Novum 10/11-21, Ortho-Novum 10/11-28, Ortho-Novum 7/14-21, Ortho-Novum 7/14-28, Ortho-Novum 7/7/7-21, Ortho-Novum 7/7/7-28, Ovcon-35, Ovcon-50, Philith, Pirmella 1/35, Pirmella 7/7/7, Tri-Norinyl 21-Day, Tri-Norinyl 28-Day, Vyfemla, Wera)
  • Ethinylestradiol and norethisterone acetate [and/or ferrous fumarate (Fe)] (Blisovi 24 Fe, Blisovi Fe 1.5/30, Blisovi Fe 1/20, Estrostep 21, Estrostep Fe, Fyavolv, Gildess 1.5/30, Gildess 1/20, Gildess 24 Fe, Gildess Fe 1.5/30, Gildess Fe 1/20, Junel 1.5/30, Junel 1/20, Junel Fe 1.5/30, Junel Fe 1/20, Larin 1.5/30, Larin 1/20, Larin 24 Fe, Larin Fe 1.5/30, Larin Fe 1/20, Leribane, Lo Loestrin Fe, Lo Minastrin Fe, Lo-Blisovi Fe, Loestrin 21 1.5/30, Loestrin 21 1/20, Loestrin 24 Fe, Loestrin Fe 1.5/30, Loestrin Fe 1/20, Mibelas 24 Fe, Microgestin 1.5/30, Microgestin Fe 1/20, Minastrin 24 Fe, Norlestrin 21 1/50, Norlestrin 21 2.5/50, Norlestrin 28 1/50, Norlestrin Fe 1/50, Norlestrin Fe 2.5/50, Taytulla, Tri-Legest 21, Tri-Legest Fe)
  • Ethinylestradiol and norgestimate (Estarylla, Mili, Mono-Linyah, Ortho Cyclen-21, Ortho Cyclen-28, Ortho Tri-Cyclen, Ortho Tri-Cyclen 21, Ortho Tri-Cyclen 28, Ortho Tri-Cyclen Lo, Previfem, Sprintec, Tri Lo Sprintec, Tri-Estarylla, Tri-Linyah, Tri-Lo-Estarylla, Tri-Lo-Linyah, Tri-Mili, Tri-Previfem, Tri-Sprintec)
  • Ethinylestradiol and norgestrel (Cryselle, Elinest, Lo/Ovral, Lo/Ovral-28, Low-Ogestrel-21, Low-Ogestrel-28, Ogestrel 0.5/50-21, Ogestrel 0.5/50-28, Ovral, Ovral-28)
  • Mestranol and norethisterone (Norinyl 1+50 28-Day)

Transdermal patches

Vaginal rings

Combined injectable contraceptives

Estradiol cypionate and medroxyprogesterone acetate (Lunelle; 5 mg / 25 mg) was previously available in the U.S. but was discontinued.

Progestogen-only contraceptives

Progestogen-only pills

Norgestrel (Ovrette; 0.075 mg) was previously available in the U.S. but was discontinued.

Postcoital emergency contraceptive pills

  • Levonorgestrel (Athentia Next, Fallback Solo, Her Style, Opcicon One-Step, Plan B, Plan B One-Step) – 0.75 mg, 1.5 mg

Progestogen-only injectable contraceptives

Intrauterine devices

  • Levonorgestrel (Kyleena, Liletta, Mirena, Skyla) – 13.5 mg/device, 19.5 mg/device, 52 mg/device

Progesterone (Progestasert; 38 mg/device) was previously available in the U.S. but was discontinued.

Subcutaneous implants

  • Etonogestrel (Implanon, Nexplanon) – 68 mg/implant
  • Levonorgestrel (Jadelle, Norplant, Norplant System in Plastic Container) – 36 mg/implant, 75 mg/implant

For other uses

Combined with estrogen

Oral pills

Estradiol/progesterone (TX-001HR), a combination of estradiol and progesterone in oil-filled capsules, is currently pending approval.[2]

Estradiol and norgestimate (Prefest; 1 mg / 90 μg) was previously available in the U.S. but was discontinued.

Transdermal patches

Progestogen-only

Oral pills

Atypical:

  • Danazol (Danocrine) – 50 mg, 100 mg, 200 mg – approved specifically for the treatment of endometriosis

Oral suspensions

Vaginal tablets

Vaginal gels

Intramuscular injectables

Miscellaneous

  • Norethisterone acetate and leuprorelin (Lupaneta Pack) – 5 mg norethisterone acetate oral pills, 3.75 mg/vial, 11.25 mg/vial leuprorelin for intramuscular injection – approved specifically for the treatment of painful endometriosis

Not available in the United States

See also

Notes

  1. Brian Park, PharmD (16 September 2019). "Slynd, a Progestin-Only Contraceptive, Now Available". Monthly Prescribing Reference (MPR). Haymarket Media, Inc. Retrieved 5 January 2020.
  2. Pickar JH, Bon C, Amadio JM, Mirkin S, Bernick B (2015). "Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy". Menopause. 22 (12): 1308–16. doi:10.1097/GME.0000000000000467. PMC 4666011. PMID 25944519.
  3. Jame Abraham; James L. Gulley; Carmen J. Allegra (1 September 2009). Bethesda Handbook of Clinical Oncology. Lippincott Williams & Wilkins. pp. 612–. ISBN 978-0-7817-9558-6.
  4. Guido Eibl; Mouad Edderkaoui (22 April 2015). Risk Factors for Pancreatic Cancer: Underlying Mechanisms and Potential Targets. Frontiers Media SA. pp. 96–. ISBN 978-2-88919-468-1. In 1993, the Food and Drug Administration (FDA) approved megestrol acetate for the treatment of cancer anorexia-cachexia syndrome as well as cachexia due to chronic conditions, including human acquired immunodeficiency syndrome (AIDS).

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.